Premium
Bayesian decision theoretic two‐stage design in phase II clinical trials with survival endpoint
Author(s) -
Zhao Lili,
Taylor Jeremy M.G.,
Schuetze Scott M.
Publication year - 2012
Publication title -
statistics in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.996
H-Index - 183
eISSN - 1097-0258
pISSN - 0277-6715
DOI - 10.1002/sim.4511
Subject(s) - bayes' theorem , event (particle physics) , statistics , bayesian probability , early stopping , sequential analysis , sample size determination , computer science , stage (stratigraphy) , decision rule , mathematics , econometrics , artificial intelligence , paleontology , physics , quantum mechanics , artificial neural network , biology
In this paper, we consider two‐stage designs with failure‐time endpoints in single‐arm phase II trials. We propose designs in which stopping rules are constructed by comparing the Bayes risk of stopping at stage I with the expected Bayes risk of continuing to stage II using both the observed data in stage I and the predicted survival data in stage II. Terminal decision rules are constructed by comparing the posterior expected loss of a rejection decision versus an acceptance decision. Simple threshold loss functions are applied to time‐to‐event data modeled either parametrically or nonparametrically, and the cost parameters in the loss structure are calibrated to obtain desired type I error and power. We ran simulation studies to evaluate design properties including types I and II errors, probability of early stopping, expected sample size, and expected trial duration and compared them with the Simon two‐stage designs and a design, which is an extension of the Simon's designs with time‐to‐event endpoints. An example based on a recently conducted phase II sarcoma trial illustrates the method. Copyright © 2012 John Wiley & Sons, Ltd.